March 26, 2020 / 8:22 PM / 13 days ago

BRIEF-Dicerna No Longer Expects To Complete Enrollment In Phyox2 In Q2

March 26 (Reuters) - Dicerna Pharmaceuticals Inc:

* DICERNA PHARMACEUTICALS - INSTITUTING MEASURES TO ENSURE CONTINUITY OF CARE AND CONTINUED DOSING OF PATIENTS CURRENTLY ENROLLED IN PHYOX2 TRIAL

* DICERNA PHARMACEUTICALS INC - NO LONGER EXPECTS TO COMPLETE ENROLLMENT IN PHYOX2 IN Q2 OF 2020 AS PREVIOUSLY PROJECTED

* DICERNA PHARMACEUTICALS - EXPECTS A MODIFIED PROTOCOL WOULD ENABLE PHYOX3 TRIAL TO CONTINUE ACCORDING TO PLAN FOR MOST PARTICIPANTS

* DICERNA PHARMACEUTICALS - EXPECTS PAUSE IN ENROLLMENT AT HIGHER DOSES IN DCR-A1AT PHASE 1/2 TRIAL FOR ALPHA-1 ANTITRYPSIN DEFICIENCY IS LIKELY

* DICERNA PHARMACEUTICALS - SUPPLY OF CO’S INVESTIGATIONAL MEDICINES IS SUFFICIENT TO SUPPORT ONGOING CLINICAL TRIALS

* DICERNA PHARMACEUTICALS - CONTINUES TO BELIEVE AVAILABLE CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES TO BE SUFFICIENT TO FUND OPERATIONS INTO 2023 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below